Relmada Therapeutics posted second‑quarter earnings per share of $‑0.11, topping the $‑0.20 consensus estimate by $0.09. The narrower loss underscores progress on its NDV‑01 and sepranolone programs and gives investors confidence the company can sustain operations with its $217.7 million cash runway.
Key Highlights
- Cash balance of $217.7 million provides runway through 2029, supporting Phase 3 RESCUE and IND filings
- R&D expense rose to $8.4 million, up $5.6 million from prior year, reflecting higher NDV‑01 and sepranolone study costs
- Short interest 12% of shares outstanding, 8.5 days volume to cover, up 22% from prior settlement
The beat provides a tangible proof point for investors monitoring the company’s ability to manage cost growth while advancing its pipeline, a factor that can influence valuation multiples amid a volatile biotech sector.
EPS Beat and Share Reaction
The EPS surprise stems from a modest net loss of $12.9 million for the quarter, compared with a $9.9 million loss in the same period last year. Operating cash outflow rose to $9.6 million from $6.4 million a year earlier, reflecting heightened R&D spend. Investors will watch whether this earnings improvement translates into sustained price appreciation, especially as short interest sits at 12% of shares and 8.5 days of volume to cover, signaling a moderate level of bearish positioning.
Cash Runway and Cost Profile
Relmada’s cash and short‑term investments total $217.7 million, more than double the $93.0 million reported at the end of 2025. The company says the balance funds operations through 2029, comfortably covering the Phase 3 RESCUE program for NDV‑01. R&D expense climbed to $8.4 million, a $5.6 million increase driven by higher study and manufacturing costs, while general and administrative expense fell to $6.6 million from $7.4 million, helped by lower stock‑based compensation.
The net cash outflow of $9.6 million underscores the need for disciplined spending, and the sizable cash pool may temper dilution concerns for shareholders awaiting future financing events.
Pipeline Progress and Upcoming INDs
The company advanced manufacturing activities for NDV‑01, a sustained‑release intravesical gemcitabine/docetaxel formulation targeting non‑muscle invasive bladder cancer, and expects to file a U.S. IND by year‑end 2026. Upon IND clearance, the Phase 3 RESCUE registrational program will launch, positioning NDV‑01 as a potential best‑in‑class therapy. Sepranolone, a synthetic isoallopregnanolone aimed at Prader‑Willi Syndrome, is also slated for a year‑end IND filing followed by a Phase 2 proof‑of‑concept study.
Outlook and Upcoming Catalyst
That event offers a platform for analysts to probe the feasibility of the upcoming IND submissions and the company’s cash deployment strategy. With short interest rising 22% from the prior settlement, market participants will gauge whether the upcoming data releases and execution milestones can alleviate bearish pressures. The next catalyst will be the IND filing decisions later in the year, which will dictate the trajectory of both NDV‑01 and sepranolone programs and set the stage for future valuation assessments.
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...